Phase 3 Apitegromab Trial Planned for Non-ambulatory Types 2, 3

Phase 3 Apitegromab Trial Planned for Non-ambulatory Types 2, 3

308055

Phase 3 Apitegromab Trial Planned for Non-ambulatory Types 2, 3

Scholar Rock plans to soon initiate a Phase 3 clinical trial of apitegromab, its investigational muscle-directed treatment for spinal muscular atrophy (SMA), in type 2 and 3 patients who are unable to walk. “We anticipate initiating a Phase 3 trial to evaluate apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA by the end of 2021 as we work towards our aim of establishing apitegromab as the potential first muscle-directed therapy to treat SMA,”…

You must be logged in to read/download the full post.